Lessons learned? [Regulatives / Guidelines]

posted by d_labes  – Berlin, Germany, 2011-08-24 13:24 (5421 d 11:17 ago) – Posting: # 7302
Views: 8,783

Dear brothers-in-arms!

What does this all tell us? What lessons learned? :confused:

First I hope that the statisticians at EMA responsible for that paragraph of the Q&A read this thread. It must be a splashy slap in their face considering Helmut's quotation of "the spirit of EMA’s Q&A".

Second I come more and more to the conclusion that a decomposition of the subject effect into the terms sequence and subject nested within sequence is not really possible with those crippled datasets (reasons not really understood, but I'm only a bloody amateur and have no such deep understanding of concepts like rank of the model.matrix). The robust model without any peculiarities should therefore include period and subject effects only.
Do I err here?

Third the intra-individual variability (represented by the residual error) is fortunately not affected by all that muddle. And this is the only interesting number in this analysis. The rest is really "scheissegal" (best vulgar translation found: don't give a flying fuck :-D).
Also I personally have a deep horror to see df=0 or 'not estimable' in a model.

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,572 registered users;
366 visitors (0 registered, 366 guests [including 30 identified bots]).
Forum time: 00:42 CEST (Europe/Vienna)

Don’t compromise yourself.
You are all you’ve got.    Janis Joplin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5